Chronic Lymphocytic Leukemia
FDA approves Jaypirca for chronic lymphocytic leukemia, small lymphocytic lymphoma
The FDA granted accelerated approval to pirtobrutinib for the treatment of adults with chronic lymphocytic leukemia or small lymphocytic lymphoma.
FDA grants priority review to therapy for relapsed leukemia, lymphoma
The FDA announced several regulatory actions.
MB-106 induces response in indolent lymphoma
An investigational chimeric antigen receptor T-cell therapy induced responses among patients with indolent lymphomas, according to topline data released by the agent’s manufacturer.
VIDEO: COVID adds difficulty in interpreting results of randomized trials
In this video, Jakub Svoboda, MD, discusses the results of the phase 3 Alliance study, pertaining to chronic lymphocytic leukemia, presented at ASCO Annual Meeting.
VIDEO: MOLTO study probes combination therapy in Richter syndrome
In this video, Jakub Svoboda, MD, discusses updated data on the results of the MOLTO study into Richter syndrome presented at ASCO Annual Meeting.
VIDEO: Liso-cel could have ‘best shot’ at remission for double refractory CLL
In this video, Jakub Svoboda, MD, discusses updated data on the results of lisocabtagene maraleucel chimeric antigen receptor T-cell therapy on chronic lymphocytic leukemia, presented at ASCO Annual Meeting.
VIDEO: Liso-cel CAR-T treatment shows strong results in patients with CLL
In this video, Michael Choi, MD, discusses updated data on the results of liso-cel chimeric antigen receptor T-cell treatments on chronic lymphocytic leukemia, presented at ASCO Annual Meeting.
VIDEO: Alliance study shows two-drug combination has better results than three in CLL
In this video, Michael Choi, MD, discusses the results of the phase 3 Alliance study, pertaining to chronic lymphocytic leukemia, presented at ASCO Annual Meeting.
Venetoclax regimen not superior to standard therapy alone for older patients with CLL
CHICAGO — The addition of venetoclax to ibrutinib and obinutuzumab did not extend PFS among older patients with treatment-naive chronic lymphocytic leukemia during the COVID-19 pandemic, according to data presented at ASCO Annual Meeting.
Liso-cel CAR-T ‘new potential treatment option’ for advanced chronic lymphocytic leukemia
CHICAGO — Lisocabtagene maraleucel significantly improved complete remission rates among adults with relapsed or refractory chronic lymphocytic leukemia, results from the pivotal phase 2 TRANSCEND CLL 004 trial showed.